Strong Multinational Growth Performance Despite Economic Slowdown
BMI View: In line with our optimism towards the Chinese healthcare sector, many multinational pharmaceutical firms continue to record healthy double-digit revenue growth in Q114, despite the economic slowdown. Given the attractiveness of the Chinese pharmaceutical market (due to its ageing population, increasingly personal wealth and government support for healthcare), we expect continued investments from foreign investors into the pharmaceutical and healthcare sector.
The majority of multinational pharmaceutical firms that have disclosed their sales figures in China in Q114 achieved strong double digit growth, in line with our long-term optimism towards the Chinese pharmaceutical and healthcare sector.
|Revenues Generated In China By Selected Multinational Pharmaceutical Firms (USDmn)|